Deng Yanli, Zhang Leixiao, Wen Aiwei, Xu Dongxian, Wang Wenping, Hou Yuhao, Liu Zhen, Yang Lin, Shen Tao, Luo Qin, Wu Wei, Ou Yuanshu
Nephropathy Department, Sichuan Second Chinese Medicine Hospital.
Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Medicine (Baltimore). 2020 Jun 5;99(23):e20622. doi: 10.1097/MD.0000000000020622.
Nephrotic syndrome (NS) is a common chronic recurrent kidney disease. Many trials have shown that Chinese medicine prescription (CMP) can effectively treat NS. The program aims to evaluate the efficacy and safety of CMP for NS.
This systematic evaluation will entail an electronic and manual search of all CMP for NS from inception to February, 2020, regardless of the publication status or language. Databases include PubMed, Embase, Springer, Web of Science, the Cochrane Library, the World Health Organization International Clinical Trial Registration Platform, the Chinese Medicine Database, the China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the China Science Journal Database, and the Wanfang Database. Other sources of information, including bibliographies and meeting minutes for identified publications, will also be searched. A manual search for grey literature, including unpublished conference articles will be performed. Additionally, any clinical randomized controlled trials related to CMP for NS, regardless of the publication status and language limitations, will be included in the study. Study selection, data extraction, and research quality assessments will be conducted independently by 2 researchers. The main result was the total clinical efficacy rate or other validated scales after at least 2 weeks of treatment. Secondary outcomes included 24-hour urine protein quantification, blood urea nitrogen, serum creatinine, C-reactive protein, tumor necrosis factor-α, and interleukin 6, recurrence rates and adverse events during follow-up. Implement the Cochrane RevMan V5.3 bias assessment tool to assess bias risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). Mean difference, standard mean deviation and binary data will be used to represent continuous results.
This study will provide a comprehensive review and evaluation of CMP for the treatment of NS.
This study will provide new evidence for evaluating the effectiveness and side effects of CMP on NS. Since the data is not personalized, formal ethical approval is not required.
INPLASY202040181.
肾病综合征（NS）是一种常见的慢性复发性肾脏疾病。许多试验表明，中药方剂（CMP）可有效治疗NS。本项目旨在评估CMP治疗NS的疗效和安全性。
本系统评价将对从开始到2020年2月所有治疗NS的CMP进行电子和人工检索，无论其发表状态或语言如何。数据库包括PubMed、Embase、Springer、Web of Science、Cochrane图书馆、世界卫生组织国际临床试验注册平台、中药数据库、中国知网、中国生物医学文献数据库、中国科学期刊数据库和万方数据库。还将检索其他信息来源，包括已识别出版物的参考文献和会议记录。将进行人工检索灰色文献，包括未发表的会议文章。此外，任何与治疗NS的CMP相关的临床随机对照试验，无论其发表状态和语言限制如何，都将纳入本研究。研究选择、数据提取和研究质量评估将由两名研究人员独立进行。主要结果是治疗至少2周后的总临床有效率或其他经过验证的量表。次要结果包括24小时尿蛋白定量、血尿素氮、血清肌酐、C反应蛋白、肿瘤坏死因子-α和白细胞介素6、随访期间的复发率和不良事件。采用Cochrane RevMan V5.3偏倚评估工具评估偏倚风险、数据整合风险、荟萃分析风险和亚组分析风险（如条件满足）。均值差、标准化均值差和二分类数据将用于表示连续结果。
本研究将对CMP治疗NS进行全面的综述和评价。
本研究将为评估CMP治疗NS的有效性和副作用提供新的证据。由于数据不涉及个人信息，无需正式伦理批准。
INPLASY注册号：INPLASY202040181。
